Quarterly report pursuant to Section 13 or 15(d)

Financial Instruments (Tables)

v2.4.0.6
Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2012
Investments, All Other Investments [Abstract]  
Summary of the assets and liabilities measured at fair value on recurring basis
The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2012 (in thousands):

Fair Value Measurements at Reporting Date Using
 
 
 
Quoted Prices in
Active Markets
for Identical
Assets
 
Significant
Other
Observable
Inputs
 
Significant
Unobservable
Inputs
 
Total
 
(Level 1)
 
(Level 2)
 
(Level 3)
Assets:
 
 
 
 
 
 
 
Certificates of deposit
$

 
$

 
$

 
$

Liabilities:
 
 
 
 
 
 
 
Current portion of contingent liabilities - CyDex
$
323

 
$

 
$

 
$
323

Liability for contingent value rights - Metabasis

 

 

 

Liability for contingent value rights – Neurogen
500

 

 

 
500

Long-term portion of contingent liabilities - CyDex
7,235

 

 

 
7,235

Total liabilities
$
8,058

 
$

 
$

 
$
8,058


The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2011 (in thousands):

Fair Value Measurements at Reporting Date Using
 
 
 
Quoted Prices in
Active Markets
for Identical
Assets
 
Significant
Other
Observable
Inputs
 
Significant
Unobservable
Inputs
 
Total
 
(Level 1)
 
(Level 2)
 
(Level 3)
Assets:
(Restated)
 
 
 
 
 
(Restated)
Certificates of deposit
$
10,000

 
$
10,000

 
$

 
$

Liabilities:
 
 
 
 
 
 
 
Current portion of contingent liabilities - CyDex
$
6,879

 
$

 
$

 
$
6,879

Liability for contingent value rights - Metabasis
1,068

 
1,068

 

 

Liability for contingent value rights – Neurogen
700

 

 

 
700

Long-term portion of contingent liabilities - CyDex
8,651

 

 

 
8,651

Total liabilities
$
17,298

 
$1,068
 
$

 
$
16,230